[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534159":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":42,"locations":48,"responsibleParty":156,"collaborators":158,"id":167,"slug":28,"hasResults":168,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":28,"eligibilityCriteria":172,"healthyVolunteers":168,"sex":173,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":28,"studyType":179,"phases":180,"briefSummary":182,"conditions":183,"keywords":28,"overallStatus":51,"whyStopped":28,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":194},{"fullName":5,"class":6},"Eye & ENT Hospital of Fudan University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"The control group","ACTIVE_COMPARATOR","Endoscopic surgery + adjuvant therapy",[13,14],"Procedure: endoscopic surgery","Drug: Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy",{"label":16,"type":17,"description":18,"interventionNames":19},"The experimental group","EXPERIMENTAL","Neoadjuvant therapy +endoscopic surgery + adjuvant therapy",[13,20,21],"Drug: Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy","Drug: Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy",[23,29,34,38],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"PROCEDURE","endoscopic surgery","The tumor was resected by endoscopic nasopharyngectomy.",[9,16],null,{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":28},"DRUG","Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy","Two courses of Toripalimab Injection and two courses of Toripalimab Injection and Gemcitabine based chemotherapy were given before endoscopic surgery.",[16],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":28},"Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy","Eight courses of Toripalimab Injection and two to four courses of chemotherapy, or until unacceptable side effects.",[16],{"type":30,"name":39,"description":40,"armGroupLabels":41,"otherNames":28},"Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy","Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.",[9],[43],{"name":44,"role":45,"phone":46,"phoneExt":28,"email":47},"Xiaole Song","CONTACT","+8621 64377134","jxfxsxl@163.com",[49,74,89,103,118,129,142],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Eye& ENT Hospital, Fudan University","RECRUITING","Shanghai","Shanghai Municipality","200031","China",{"type":57,"coordinates":58},"Point",[59,60],121.45806,31.22222,{"lat":60,"lon":59},[63,65,68,70,72],{"name":44,"role":45,"phone":64,"phoneExt":28,"email":47},"15821388769",{"name":66,"role":67,"phone":28,"phoneExt":28,"email":28},"Hongmeng Yu","PRINCIPAL_INVESTIGATOR",{"name":44,"role":69,"phone":28,"phoneExt":28,"email":28},"SUB_INVESTIGATOR",{"name":71,"role":69,"phone":28,"phoneExt":28,"email":28},"Li Yan",{"name":73,"role":69,"phone":28,"phoneExt":28,"email":28},"Yuting Lai",{"facility":75,"status":76,"city":77,"state":28,"zip":28,"country":55,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Fujian Medical University Union Hospital","NOT_YET_RECRUITING","Fuzhou",{"type":57,"coordinates":79},[80,81],119.30611,26.06139,{"lat":81,"lon":80},[84,86,87],{"name":85,"role":45,"phone":28,"phoneExt":28,"email":28},"Desheng Wang",{"name":85,"role":67,"phone":28,"phoneExt":28,"email":28},{"name":88,"role":69,"phone":28,"phoneExt":28,"email":28},"Haichun Lai",{"facility":90,"status":51,"city":91,"state":28,"zip":28,"country":55,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"The People's Hospital of Guangxi Zhuang Autonomous Region","Nanning",{"type":57,"coordinates":93},[94,95],108.31667,22.81667,{"lat":95,"lon":94},[98,100,101],{"name":99,"role":45,"phone":28,"phoneExt":28,"email":28},"Shenhong Qu",{"name":99,"role":67,"phone":28,"phoneExt":28,"email":28},{"name":102,"role":69,"phone":28,"phoneExt":28,"email":28},"Jingjin Weng",{"facility":104,"status":76,"city":52,"state":28,"zip":28,"country":55,"cosmosGeoPoint":105,"geoPoint":107,"contacts":108},"Changhai Hospital",{"type":57,"coordinates":106},[59,60],{"lat":60,"lon":59},[109,111,112,114,116],{"name":110,"role":45,"phone":28,"phoneExt":28,"email":28},"Haihong Tang",{"name":110,"role":67,"phone":28,"phoneExt":28,"email":28},{"name":113,"role":69,"phone":28,"phoneExt":28,"email":28},"Hongliang Zheng",{"name":115,"role":69,"phone":28,"phoneExt":28,"email":28},"Haopu Li",{"name":117,"role":69,"phone":28,"phoneExt":28,"email":28},"Fengya Pan",{"facility":119,"status":76,"city":52,"state":28,"zip":28,"country":55,"cosmosGeoPoint":120,"geoPoint":122,"contacts":123},"Shanghai Sixth People's Hospital",{"type":57,"coordinates":121},[59,60],{"lat":60,"lon":59},[124,126,127],{"name":125,"role":45,"phone":28,"phoneExt":28,"email":28},"Weitian Zhang",{"name":125,"role":67,"phone":28,"phoneExt":28,"email":28},{"name":128,"role":69,"phone":28,"phoneExt":28,"email":28},"Ru Tang",{"facility":130,"status":76,"city":52,"state":28,"zip":28,"country":55,"cosmosGeoPoint":131,"geoPoint":133,"contacts":134},"Shanghai Zhongshan Hospital",{"type":57,"coordinates":132},[59,60],{"lat":60,"lon":59},[135,137,138,140],{"name":136,"role":45,"phone":28,"phoneExt":28,"email":28},"Xinsheng Huang",{"name":136,"role":67,"phone":28,"phoneExt":28,"email":28},{"name":139,"role":67,"phone":28,"phoneExt":28,"email":28},"Xianhui Ning",{"name":141,"role":67,"phone":28,"phoneExt":28,"email":28},"Lei Zhou",{"facility":143,"status":76,"city":144,"state":28,"zip":28,"country":55,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Shenzhen Second People's Hospital","Shenzhen",{"type":57,"coordinates":146},[147,148],114.0683,22.54554,{"lat":148,"lon":147},[151,153,154],{"name":152,"role":45,"phone":28,"phoneExt":28,"email":28},"Yongtian Lu",{"name":152,"role":67,"phone":28,"phoneExt":28,"email":28},{"name":155,"role":67,"phone":28,"phoneExt":28,"email":28},"Jing Tao",{"type":157,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[159,160,162,163,164,166],{"name":130,"class":6},{"name":161,"class":6},"Shanghai 6th People's Hospital",{"name":104,"class":6},{"name":75,"class":6},{"name":165,"class":6},"People's Hospital of Guangxi Zhuang Autonomous Region",{"name":143,"class":6},"100534159",false,"NCT06235203","Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC","Neoadjuvant-Adjuvant Versus Adjuvant-Only Therapy Combined With Endoscopic Surgery in Advanced Recurrent Nasopharyngeal Carcinoma:A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Pathologically diagnosed with recurrent nasopharyngeal carcinoma;\n2. Resectable disease staging rT2 (deep parapharyngeal space, or distance to the internal carotid ≤5mm) or rT3 (excluding the lesions confined to the basal wall of sphenoid sinus), rT4, according to AJCC 8th edition;\n3. Cervical lymph node metastasis can be controlled locally;\n4. Aged 18 to 75 years;\n5. Informed consent forms signed to participate in the trial;\n6. Without distant metastasis;\n7. ≥6months from the accomplishment of radical radiation to recurrence\n8. previously only 1 course of radiotherapy;\n9. Sufficient organ function;\n10. ECOG score 0-2 and can tolerate surgery,chemotherapy and immunotherapy.\n\nExclusion Criteria:\n\n1. Participate in other interventional clinical trials;\n2. Uncontrolled illnesses that interfere with the therapy;\n3. Suffering from another or multiple malignancy within 5 years (excluding fully treated basal cell or skin squamous cell carcinoma, cervical carcinoma in situ, etc.);\n4. Any contradiction to surgery;\n5. With serious autoimmune disease;\n6. The patient is currently using immunosuppressive agents or systemic hormone therapy to achieve immunosuppressive effects (dosage\\>10mg\u002Fday prednisone or other glucocorticoids), and continues to use them within 2 weeks before the first administration;\n7. Severe allergic reactions to other monoclonal antibodies;\n8. History of radioactive particle planting;\n9. Vaccination with live vaccine within 4 weeks prior to initial administration or possibly during the study period;\n10. Female patients who are at pregnancy or lactation;\n11. Other situations that the researchers believe not suitable for enrollment","ALL","18 Years","75 Years",{"count":177,"type":178},154,"ESTIMATED","INTERVENTIONAL",[181],"PHASE3","A multicenter randomized controlled study of surgery combined with neoadjuvant and adjuvant therapy for locally advanced recurrent nasopharyngeal carcinoma in comparison to surgery combined with adjuvant therapy",[184],"Recurrent Nasopharyngeal Carcinoma","2025-05-28",{"date":187,"type":188},"2025-06-03","ACTUAL",{"date":190,"type":188},"2024-07-09",{"date":192,"type":178},"2027-06-30",{"name":5,"class":6},7]